New treatments targeting B7-H3 for advanced prostate cancer
Novel Approaches Targeting B7-H3 in Castration-resistant Prostate Cancer
Testing whether therapies that target the B7-H3 protein can help men with castration-resistant prostate cancer, especially tumors with PTEN and TP53 changes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11245738 on NIH RePORTER |
What this research studies
This project focuses on a protein called B7-H3 that is often overproduced in aggressive, treatment-resistant prostate cancers. Researchers will use genetically engineered mouse models that mimic PTEN/TP53-deficient tumors, along with laboratory and immune-profiling techniques, to see how B7-H3 shapes the tumor environment. The team aims to develop biomarker-guided B7-H3-targeted therapies (for example antibody-based approaches) and understand which tumors are most likely to respond. Findings will guide future treatments offered to patients whose tumors show these specific molecular changes.
Who could benefit from this research
Good fit: Ideal candidates are men with metastatic castration-resistant prostate cancer whose tumors have PTEN and TP53 deletions or mutations and high B7-H3 expression.
Not a fit: People whose prostate cancers do not overexpress B7-H3 or lack PTEN/TP53 defects are less likely to benefit from B7-H3-targeted approaches.
Why it matters
Potential benefit: Could provide a new targeted treatment option for people with PTEN/TP53-deficient castration-resistant prostate cancer and improve outcomes for this hard-to-treat subgroup.
How similar studies have performed: Targeting B7-H3 is an emerging strategy with encouraging preclinical data and early clinical signals, but biomarker-guided therapies remain largely unproven in late-stage trials.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Zhao, Di — University of Tx Md Anderson Can Ctr
- Study coordinator: Zhao, Di
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.